Guardant Health Inc (GH) Stock Price & News

Q3 2026 earnings • released • EPS beat +7,77% • Revenue beat +2,95%

See results

GH:NASDAQ

Guardant Health Inc

USD 153,43

-8,99%

(-15,15) 1D

USD 135,01

-12,01% (-18,42)

After hours

Closed: 5 Nov., 16:00:02 GMT-5 · USD

All symbols

	Symbol	Price	Change	% Change

Generating top insights for GH...

Open

USD 165,00

High

USD 165,10

Low

USD 151,92

Mkt. cap

20,59 mjd

Avg. vol.

1,81 m

Volume

4,08 m

52-wk high

USD 191,01

52-wk low

USD 74,55

EPS

-USD 3,50

Beta

1,67

Shares outstanding

134,20 m

No. of employees

2 k

Open

USD 165,00

High

USD 165,10

Low

USD 151,92

Mkt. cap

20,59 mjd

Avg. vol.

1,81 m

Volume

4,08 m

52-wk high

USD 191,01

52-wk low

USD 74,55

EPS

-USD 3,50

Beta

1,67

Shares outstanding

134,20 m

No. of employees

2 k

Related stocks

Twist Bioscience Corp

USD 120,61

-15,41%

News stories

From web sources and news partners

TradingView

29 minute gelede

Guardant Health, Inc. reports results for the quarter ended September 30 - Earnings Summary

BigGo Finance

54 minute gelede

Guardant Health Stock Slides 12% After Cash Burn Forecast Widens Despite Revenue Beat

Investing.com

2 uur gelede

Guardant Health falls 12% as cash burn guidance disappoints

Benzinga

2 uur gelede

Guardant Health Q3 2026 Earnings Call Transcript

Profile

Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers. Wikipedia

About Guardant Health Inc

CEOHelmy Eltoukhy | AmirAli Talasaz

Employees2,5 k

Founded2012

HeadquartersPalo Alto, Kalifornië, Verenigde State van Amerika

SectorHealth Care

IndustryHealth care provider

Websiteguardanthealth.com

Analyst ratings

Based on 14 analysts giving stock ratings to GH in the past 3 months

Strong buy

Buy

Hold

Sell

12-month forecast

Based on 14 Wall Street analysts offering 12 month price targets for GH in the last 3 months.

Highest

Current USD 153,43

USD 225,00 (+46,65%)

Average

USD 206,75 (+34,75%)

Lowest

USD 193,00 (+25,79%)

Analyst	Recommendation	Action	Price target	Projected	Date
Mark Massaro BTIG	Buy	Maintained	USD 210,00	+36,9%	10/27/2026
Max Masucci Roth MKM	Buy	Initiated	USD 200,00	+30,4%	10/22/2026
Kallum Titchmarsh Morgan Stanley	Buy	Maintained	USD 200,00	+30,4%	10/20/2026
Eve Burstein Bernstein	Buy	Reiterated	USD 210,00	+36,9%	10/19/2026
Casey Woodring J.P. Morgan	Buy	Maintained	USD 195,00	+27,1%	10/14/2026
Lu Li Bank of America Securities	Buy	Maintained	USD 200,00	+30,4%	10/09/2026
Michael Ryskin Bank of America Securities	Buy	Maintained	USD 200,00	+30,4%	10/09/2026
Luke Sergott Barclays	Buy	Maintained	USD 220,00	+43,4%	10/07/2026
Subbu Nambi Guggenheim	Buy	Maintained	USD 200,00	+30,4%	10/01/2026
Evie Koslosky Goldman Sachs	Buy	Maintained	USD 225,00	+46,6%	09/20/2026
William Bonello Craig-Hallum	Buy	Maintained	-	-	09/15/2026
David Westenberg Piper Sandler	Buy	Maintained	USD 193,00	+25,8%	09/15/2026
Unknown Analyst UBS	Buy	Maintained	USD 225,00	+46,6%	09/09/2026
Doug Schenkel UBS	Buy	Maintained	USD 225,00	+46,6%	09/09/2026
Jamie Clark Rothschild & Co Redburn	Buy	Initiated	USD 203,00	+32,3%	09/08/2026
Matt Larew William Blair	Buy	Maintained	-	-	09/08/2026
Bradley Bowers Mizuho Securities	Buy	Maintained	USD 200,00	+30,4%	08/04/2026
Mason Carrico Stephens	Buy	Maintained	USD 195,00	+27,1%	08/04/2026
Kyle Mikson CFA Canaccord Genuity	Buy	Maintained	USD 205,00	+33,6%	08/02/2026
Daniel Arias Stifel Nicolaus	Buy	Maintained	USD 180,00	+17,3%	08/03/2026
Dan Leonard RBC Capital	Buy	Reiterated	USD 200,00	+30,4%	07/31/2026
Daniel Brennan TD Cowen	Buy	Reiterated	USD 210,00	+36,9%	07/31/2026
Brandon Couillard Wells Fargo	Buy	Maintained	USD 125,00	-18,5%	07/29/2026
Patrick B Donnelly Citi	Buy	Maintained	USD 215,00	+40,1%	07/08/2026
Vijay Kumar Evercore ISI	Buy	Maintained	USD 200,00	+30,4%	07/06/2026
Puneet Souda Leerink Partners	Buy	Reiterated	-	-	06/02/2026
Paige Chamberlain‏ Wolfe Research	Buy	Reiterated	USD 150,00	-2,2%	06/01/2026
Unknown Analyst Wolfe Research	Buy	Reiterated	USD 150,00	-2,2%	06/01/2026
Andrew Brackmann William Blair	Buy	Maintained	-	-	05/27/2026
Catherine Ramsey Schulte Robert W. Baird	Buy	Maintained	USD 129,00	-15,9%	05/08/2026
Andrew Cooper Raymond James	Buy	Reiterated	USD 129,00	-15,9%	02/23/2026

All values in USD	Sep. 2025	Des. 2025	Mrt. 2026	Jun. 2026
Revenue	265,20 m	281,27 m	301,66 m	334,98 m
Cost of goods sold	93,59 m	99,49 m	104,92 m	115,95 m
Cost of revenue	93,59 m	99,49 m	104,92 m	115,95 m
Research and development expenses	89,96 m	98,26 m	91,04 m	96,53 m
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	180,53 m	204,20 m	227,06 m	250,61 m
Operating expense	270,48 m	302,46 m	318,10 m	347,15 m
Total operating expenses	364,07 m	401,96 m	423,02 m	463,10 m
Operating income	-98,87 m	-120,69 m	-121,35 m	-128,12 m
Other non operating income	-48,00 k	-4,69 m	1,55 m	308,00 k
EBT including unusual items	-92,59 m	-130,22 m	-111,70 m	-119,96 m
EBT excluding unusual items	-92,47 m	-116,52 m	-111,70 m	-118,96 m
Income tax expense	136,00 k	-1,73 m	372,00 k	185,00 k
Effective tax rate	-0,15%	1,33%	-0,33%	-0,15%
Other operating expenses	-	-	-	-
Net income	-92,72 m	-128,49 m	-112,08 m	-120,14 m
Net profit margin	-34,96%	-45,68%	-37,15%	-35,87%
Earnings per share	-0,39	-0,50	-0,45	-0,42
Interest and investment income	7,39 m	10,03 m	11,15 m	10,20 m
Interest expense	-943,00 k	-1,18 m	-3,05 m	-1,35 m
Net interest expenses	6,45 m	8,85 m	8,10 m	8,85 m
Depreciation and amortization charges	-	-	-	-
EBITDA	-89,47 m	-110,64 m	-111,91 m	-118,56 m
Gain or loss from assets sale	-	-	-	-

Ask anything